Orexo AB Aktier SK -,40
- BID
1.36
- ASK
1.46
- 1,471 Units2,100 Units
- 07/21, 21:58:33 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
16.13%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.34 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.358 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:57:11 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 1.406 | 1.346 |
| PREV. DAY'S PRICE | 1.342 | (07/20) |
| CHANGE DAY BEFORE | +0.02 | 1.19 % |
| 52 WEEK HIGH / LOW | 3.8 (10/10) | 1.32 (07/17) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.33 | -0.51 | -0.34 | -0.89 | -0.66 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 1.57(e) | - | - |
PRICE - BOOK RATIO | 9.04 | - | 2.13 | - | - |
PRICE - SALES RATIO | 0.83 | 1.02 | 40.09 | - | - |
PRICE - CASH FLOW RATIO | - | - | 6.02 | - | - |
Master Data
| WKN | A0HG6G |
| ISIN | SE0000736415 |
| SYMBOL | C5G |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | OREXO AB SK-,40 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -34.54 % | -27.77 % | -27.69 % | -51.90 % | -16.13 % | - | - | -46.00 % |
| HIGH | 2.07 | 2.24 | 2.24 | 3.03 | 3.80 | - | - | 3.29 |
| LOW | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 | - | - | 1.32 |
Dividende
pro Aktie
OREXO AB SK-,40 does not deliver dividend information
Company profile
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Commercial and HQ and Pipelines. The US Commercial segment focuses on marketing and distributing a prescription medication used for opioid dependence treatment in the US. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.